FLUAD 2025-2026 (influenza vaccine tvs 2025-26 (65 yr up)/adjuvant mf59c.1/pf)

There are 0 contraindications.

There are 1 severe contraindications. Adequate patient monitoring is recommended for safer drug use.

Severe List
Guillain-barre syndrome

There are 0 moderate contraindications.

There are 15 severe adverse reactions.

More Frequent	Less Frequent
None.	None.

Rare/Very Rare
Anaphylaxis Angioedema Bell's palsy Brachial plexus disorder Cellulitis Dyspnea Encephalopathy Guillain-barre syndrome Hypersensitivity drug reaction Myelitis Optic neuritis Serum sickness Stevens-johnson syndrome Thrombocytopenic disorder Vasculitis

There are 34 less severe adverse reactions.

More Frequent	Less Frequent
Bruising Chills Erythema Fatigue Headache disorder Induration of skin Injection site pain Injection site sequelae Malaise Myalgia Pruritus of skin	Appetite changes Arthralgia Cough Diarrhea Ecchymosis Fever Injection site erythema Injection site inflammation Nausea Pharyngitis Vomiting

Rare/Very Rare
Back pain Dizziness Extensive limb swelling after injection Flushing Lymphadenopathy Neuralgia Pain in oropharynx Paresthesia Seizure disorder Skin rash Syncope Urticaria

Data collected in a prospective pregnancy exposure registry from women vaccinated with influenza virus vaccine inactivated quadrivalent (Afluria(R), Fluarix(R), Flucelvax(R)) found no evidence of a vaccine-associated increase in the risk of major birth defects and miscarriages when administered during any trimester of pregnancy. Data for quadrivalent vaccines are relevant to trivalent products because both vaccines are manufactured using the same process and have overlapping compositions. Data are insufficient to assess the risk of use during pregnancy for other inactivated influenza vaccines (Fluzone(R), Fluad(R), Flulaval(R)).

Animal reproduction studies have not revealed evidence of harm to a fetus. Pregnant and postpartum women are at higher risk for severe influenza and influenza-related complications, particularly during the second and third trimesters, which may lead to adverse pregnancy outcomes including preterm labor and delivery. To monitor pregnancy outcomes and newborn health status following influenza vaccination of pregnant women, some manufacturers have established pregnancy registries.

It is not known whether influenza vaccine inactivated is distributed into human milk. Data are insufficient to assess effects on the breast-fed infant or on milk production. Consider the benefits of breast-feeding and importance of the vaccine to the woman; also consider potential adverse effects on the breast-fed child from the vaccine or underlying maternal condition (i.e., susceptibility to influenza infection). ACIP states that breast-feeding is not a contraindication to influenza vaccine inactivated; the vaccines do not pose any unusual risks for the mother or her nursing infant.

Afluria(R), Fluarix(R), Flucelvax(R), Flulaval(R), Fluzone(R): No overall differences in safety relative to younger adults; may be less immunogenic in geriatric individuals. Fluad(R) adjuvant-containing: Use only in adults >=65 years of age. Fluzone(R) High-Dose: Use in adults >=65 years of age.

Each 0.5 mL of Fluzone(R) High-Dose contains 4 times the amount of antigen contained in standard-dose Fluzone(R). In adults >=65 years of age, higher incidence of injection site reactions and systemic adverse effects reported with Fluzone(R) High-Dose compared with standard-dose Fluzone(R).

Some evidence that the high-dose formulation elicits higher antibody titers and higher seroconversion rates than the standard-dose formulation in adults >=65 years of age and may be more effective in preventing laboratory-confirmed influenza in this age group. ACIP states that all adults >=65 years of age should be vaccinated against influenza using influenza virus vaccine inactivated or influenza vaccine recombinant. ACIP states a preference for Fluzone(R) High-Dose, Flublok(R) recombinant influenza vaccine, or the standard-dose adjuvant-containing vaccine (Fluad(R)), but if none of these 3 vaccines is available at the time of vaccine administration, then adults >=65 years may receive a standard-dose preparation.